anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a traditional Chinese medicine formula for treating central exudative chorioretinopathy, which is characterized by being prepared from the following raw materials in parts by weight: 10-30 g of red sage root and astragalus root respectively, 5-25 g of ligusticum wallichii, 2-22 g of safflower, peach kernel, red peony root, root bark of tree peony, angelica, chrysanthemum and cassia occidentalis respectively, and 5-15 g of liquorice. One dose is taken every day, and the decoction is taken twice in the morning and at night. 1 patient at early stage generally takes 1-2 treatment courses (10 days in one treatment course), vision can be improved to the level before illness, and patients with long medical history and heavy eyeground exudation can be cured in 3-4 treatment courses. The invention has the beneficial effects that: has the function of regulating the blood circulation of the body. The blood circulation promoting and blood stasis dispelling medicine has effects of dilating blood vessel, improving microcirculation, relieving blood stasis and blood supply insufficiency, softening inflammatory exudate absorption and proliferative lesion, inhibiting bacterial growth and improving organism function. Simultaneously has the functions of improving blood circulation, promoting lymphatic return, repairing and improving the nutrition status of damaged cells and recovering the activity of the cells.
IT administration (KAT-201) will be injected via percutaneous IT injection with ultrasound and/or computed tomography (CT) guidance once a week (on Day 1 weekly). Each cycle is 28 days. Treatment will continue for up to 2 cycles until PD, unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.
Participants with moderate self-reported thoracic outlet syndrome symptoms (visual analog scale score 4-6). No intervention will be provided.
OBJECTIVES: To observe the effect of electroacupuncture (EA) at "Neiguan"(PC6) on cardiac function, cardiac morphology and transient receptor potential channel (TRPC) protein expressions in myocardial tissue of mice with myocardial hypertrophy, so as to explore its mechanisms underlying improvement of myocardial hypertrophy.
METHODS: Forty-five male C57BL/6 mice were randomly divided into control, model and EA groups (15 mice/group). The myocardial hypertrophy model was established by subcutaneous injection of isoproterenol hydrochloride (15 mg·kg-1·d-1) for 14 days. The mice of the control group received subcutaneous injection of same amount of normal saline. The mice of the EA group received EA stimulation (frequency of 2 Hz, intensity of 1 mA) of bilateral PC6 for 20 min each time, once a day for 14 consecutive days. After the intervention, the body weight, tibia length and heart weight were measured. The left ventricular ejection fraction (EF), fractional shortening index (FS), left ventricular end-systolic volume (LVEV), left ventricular end-systolic internal diameter (LVID) and left ventricular posterior wall thickness (LVPW) were measured by using echocardiography for evaluating the cardiac function. The mean number and surface area of myocardial cells was detected by wheat germ agglutinin (WGA) staining, and changes of the cardiac morphology were observed under light microscopy after HE staining. The expression levels of TRPC1, TRPC3, TRPC4 and TRPC6 (TRPC1/3/4/6) in the myocardial tissue were detected by real-time quantitative PCR (qPCR) and Western blot, separately.
RESULTS: Compared with the control group, the heart-body weight ratio(P<0.05) and heart-weight-to-tibia-length ratio (P<0.01), LVEV and LVID levels, the relative surface area, left ventricular area ratio, and the expression levels of cardiac TRPC1/3/4/6 were significantly increased (P<0.01, P<0.05), while the EF, FS, LVPW, number of cardiomyocytes, and the left ventricular posterior wall ratio were obviously decreased (P<0.01, P<0.05) in the model group. In comparison with the model group, the heart/body weight ratio, heart-weight-to-tibia-length ratio, LVEV and LVID levels, relative surface area, left ventricular area ratio, and the expression levels of cardiac TRPC1/3/4/6 were significantly decreased (P<0.01, P<0.05), while the EF, FS, LVPW, number of cardiomyocytes and left ventricular posterior wall ratio were significantly increased (P<0.01, P<0.05) in the EA group. H.E. staining showed disordered arrangement of cardiomyocytes and obvious myocardial interstitial inflammatory cell infiltration in the model group, and evident reduction of degree of cardiac fibrosis and interstitial edema in the EA group.
CONCLUSIONS: EA of PC6 can improve the cardiac function and cardiac morphology in mice with myocardial hypertrophy, which may be related to its functions in down-regulating the expression of transient receptor potential channels.
OBJECTIVES: I. Determine the feasibility and safety of combination antiretroviral therapy followed by HLA matched sibling peripheral blood stem cell or unrelated umbilical cord blood transplants in HIV infected adults with hematologic malignancies. II. Measure the effects of this treatment on HIV viral burden in the serum and tissues of these patients. III. Measure immune reconstitution following treatment in this patient population.

OUTLINE: Patients receive a combination of 3 antiretroviral agents beginning at least 3 weeks prior to the initiation of the myeloablative conditioning regimen. The antiretroviral agents are discontinued on days -5 to -1 prior to transplant. Beginning on day 0 the antiretroviral agents are restarted and continue indefinitely. Patients who are given umbilical cord blood (UCB) transplants undergo collection of autologous peripheral blood stem cells (PBSC) prior to the myeloablative conditioning regimen in case there is UCB graft failure. Prior to PBSC or UCB transplantation on day 0, all patients receive a myeloablative conditioning regimen. The conditioning regimen consists of total body irradiation twice a day on days -9 to -5 and melphalan IV over 60 minutes on days -4 to -2. Patients receiving UCB transplant also receive anti-thymocyte globulin over 6 hours on days -3 to -1. Patients are followed every 3 months for 3 years, then annually for the next 3 years.

PROJECTED ACCRUAL: A total of 6 patients will be accrued for this study over 2 years.
The present invention relates to apocynum extract and an extraction method thereof. Measurement for the apocynum extract, which is carried out wiith hyperin as a representative component, shows that the total content of flavone in the extract is from 35% to 90%. After the extract completely hydrolyzes, the content of quercetin compounds is from 30% to 80%. The content of hyperin compounds in the extract is from 15% to 55%. Separation columns of polyamide resin are adopted in the extraction method, and clarification and purification are carried out for column applying liquid by clarificant, so the service life of the separation columns can be obviously prolonged. The present invention has the characteristics that the apocynum extract is a novel substance which is firstly extracted from apocynum, the refining degree is high, most of the pharmacological activity of the apocynum is also reserved, and the dosage is much less than apocynum crude extract; the pharmacological performance and the medicine performance of the present invention are obviously better than the apocynum crude extract. The extraction method adopts the polyamide resin as a separation means, and a large number of impurities can be removed, so the present invention concentrates effective components and has low cream yield rate which is lower than 3%.
FOLLISTIM was administered as single daily subcutaneous injections in the abdomen. The starting dose of FOLLISTIM was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 375 IU. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
Sepsis-induced multiple organ dysfunction arises from the highly complex pathophysiology encompassing the interplay of inflammation, oxidative stress, endothelial dysfunction, mitochondrial damage, cellular energy failure, and dysbiosis. Over the past decades, numerous studies have been dedicated to elucidating the underlying molecular mechanisms of sepsis in order to develop effective treatments. Current research underscores liver and cardiac dysfunction, along with acute lung and kidney injuries, as predominant causes of mortality in sepsis patients. This understanding of sepsis-induced organ failure unveils potential therapeutic targets for sepsis treatment. Various novel therapeutics, including melatonin, metformin, palmitoylethanolamide (PEA), certain herbal extracts, and gut microbiota modulators, have demonstrated efficacy in different sepsis models. In recent years, the research focus has shifted from anti-inflammatory and antioxidative agents to exploring the modulation of energy metabolism and gut microbiota in sepsis. These approaches have shown a significant impact in preventing multiple organ damage and mortality in various animal sepsis models but require further clinical investigation. The accumulation of this knowledge enriches our understanding of sepsis and is anticipated to facilitate the development of effective therapeutic strategies in the future.
Apparatus and associated methods relate to management of therapeutic digital assets in a non-medical environment. In an illustrative example, non-medical digital asset(s) (NMDAs) may be evaluated relative to one or more therapeutic modalities. A corresponding therapeutic digital asset (TDA) may, for example, be generated for each therapeutically associated NMDA. The TDA may, for example, be traceably associated with corresponding risks and/or risk mitigations. Each TDA may be associated, for example, with a test profile corresponding to a risk and/or risk mitigation. A TDA may be released into a non-medical digital content delivery environment (DCDE), for example. The TDA may, for example, be monitored in the DCDE to maintain verification and/or validation (VV). A change in the DCDE affecting VV of the TDA may, for example, result in deactivation of the TDA in the DCDE. Various embodiments may advantageously permit VV of selected digital assets in a non-medical environment.
The invention relates to a nano traditional Chinese medicine used for treating diabetes and a production method thereof. The nano traditional Chinese medicine is prepared from the following raw materials containing effective ingredients in parts by weight: 50-100 parts of milkvetch root, 8-16 parts of stiff silkworm, 5-10 parts of dogwood, 18-36 parts of codonopsis pilosula and 10-20 parts of Chinese angelica. The production process comprises the steps of ultrasonic wave smashing, extraction and dispersion, microwave extraction, supersonic speed spray drying smashing, nano grinding, mixing and capsule filling. The formula lays stress on multi-synergic and multi-target effects of nano medicine, and the medicine has the advantages that the treatment effect is good and no toxic or side effect is produced. The medicine is taken in four time periods respectively by treatment skills of tonifying Qi and blood, drying dampness and resolving phlegm, regulating the flow of vital energy and removing obstruction toit, tonifying spleen and kidney as well as detoxifying and breaking silt. The medicine is pasted on local skin of human body and can be used for acupoint administration by transdermal absorption at different times, thus the diabetes is treated.
A solid wafer formulation, which readily adheres to the tongue or buccal mucosa of animals, comprises a physiologically active substance, a solid non-toxic adhesive and a non-toxic humectant and plasticizer.  Preferably the wafers have a surface area greater than 300 square millilitres and a thickness from 0,2 to 1,0 mm.  A wafer for piglets is prepared by drying a sheet of paste containing iron powder and copper powder suspended in an aqueous solution of sorbitol and sodium carboxymethylcellulose. In a second example, the active substance is calcium dioxytetracyclinne and the wafer is prepared from sodium carboxymethylcellulose, sorbitol and polyoxyethylated sorbitol. Other adhesives are hydroxyethylcellulose, a water-soluble polyethylene resin, gum tragacanth, gum arabic, gum Karaya, sodium silicate, hydrated aluminium silicate, isinglass, agar-agar, water-soluble alginate, gelatine, casein and albumen. The humectant and plasticizer may by glycerol, propylene glycol, dipropylene glycol, polyoxyethylated sorbitol, polyoxyethylated glycol, polyoxyethylated glycerol, a -methylglycerol, corn syrup or propylene glycol glucoside.
Cimetidine tablets are indicated in:

(1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION: Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine.

(2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years.

(3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks.

(4) Erosive gastroesophageal reflux (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see DOSAGE AND ADMINISTRATION: GERD).

(5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas).
Efavirenz: Efavirenz induces UDP-glucuronidase and significantly decreases posaconazole plasma concentrations  [see Clinical Pharmacology ( 12.3)].  It is recommended to avoid concomitant use of efavirenz with posaconazole unless the benefit outweighs the risks.   
Ritonavir and Atazanavir: Ritonavir and atazanavir are metabolized by CYP3A4 and posaconazole increases plasma concentrations of these drugs [see Clinical Pharmacology ( 12.3)].  Frequent monitoring of adverse effects and toxicity of ritonavir and atazanavir should be performed during coadministration with posaconazole.   
Fosamprenavir: Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended  [see Clinical Pharmacology ( 12.3)].
This trial is a randomized, longitudinal study of medical marijuana (MM) that will: (1) characterize the impact of MM on indices of addiction, such as CUD, escalation of use, tolerance, and withdrawal among those who stop using, (2) assess, via dosing diaries, the effect of MM use patterns on use of other medications, and perception of underlying disease symptomatology, (3) characterize the impact of MM on neurocognitive performance, including executive function, memory, attention, and decision-making and (4) examine evidence for impact of MM on brain structure and function. This study will enroll 200 adults with no prior history of CUD or heavy marijuana use, who express interest in using MM to treat pain, insomnia, anxiety, and/or depression. Participants will be randomly assigned to either an active MM arm (n = 100), or to a waitlist control arm (WLC) (n = 100). Participants will be assessed at baseline, regularly for 3 months, and at a 6-month and 12-month follow-up for MM use behaviors, development of CUD, perception of disease symptomatology, and neurocognitive performance. Urine collected at each visit will be assessed with quantitative assays. MRI scans will be collected to longitudinally investigate possible brain changes associated with MM use.
There have been reports of impaired or delayed wound healing in patients receiving Rapamune, including lymphocele and wound dehiscence [see Adverse Reactions (6.1)]. Mammalian target of rapamycin (mTOR) inhibitors such as sirolimus have been shown in vitro to inhibit production of certain growth factors that may affect angiogenesis, fibroblast proliferation, and vascular permeability. Lymphocele, a known surgical complication of renal transplantation, occurred significantly more often in a dose-related fashion in patients treated with Rapamune [see Adverse Reactions (6.1)]. Appropriate measures should be considered to minimize such complications. Patients with a body mass index (BMI) greater than 30 kg/m2 may be at increased risk of abnormal wound healing based on data from the medical literature.

There have also been reports of fluid accumulation, including peripheral edema, lymphedema, pleural effusion, ascites, and pericardial effusions (including hemodynamically significant effusions and tamponade requiring intervention in children and adults), in patients receiving Rapamune.
The median nerve will be defined at the proximal entrance of the carpal tunnel (scaphoid-pisiform plane). Under the ulnar approach with the in-plane technique, it was planned to hydrodissect the median nerve , using 10 cc 5% dextrose.
Object. To study the influence of Astragaloside on the activity of telomerase of senile human embryo lung fibroblasts (HELF) and the expression of anti-aging gene klotho mRNA  Method in vitro culture HELF, Astragaloside was added into experimental groups from the 50 's generation of cells, inverted microscope observes cell morphology, MTT method checks the cell vitality, Dimiri detects Galactose glucoside enzyme activity, TRAP-PCR Silver staining detects telomerase activity, RT-PCR  detects klotho mRNA expression Results Comparing with youth group both cell vitality and klotho mRNA expression in senile group decreased (P<0 01), .beta.-Galactose glucoside enzyme activity increased (P<0 01), Comparing with senile group Astragaloside could reduce .beta.-Galactose glucoside enzyme activity (P<0.01), improved cell vitality, telomerase activity and klotho mRNA expression (P<0.01) Conclusion Astragaloside plays the role of anti-aging in HELF cells by chancing cell telomerase activity and klotho gene expression "Key words" Astragaloside; telomerase; klotho, senile human embryo lung fibroblasts The study on Anti-aging effect of Astragalus is more common 1 ) in vivo study 2) serum Pharmacology study. This experiment uses replicative senile human embryo lung fibroblast cells (human embryonic lung fibroblast, HELF) as the object of study, makes the monomer composition of astragalus¨Astragaloside act directly on senile cells and observes its influence on the cell senescence and its mechanism of anti-aging effect, this provides reliable theoretical and experimental basis for confirming the anti-aging effect of Astragaloside i~ and its Molecular Pharmacology research. 1 Materials and Methods 1 1 Experimental Groups and Processing HELF cells routinely are divided as one to two and cultured when generations continue The cells younger than 35th generation represent as young cells, older than 50th generation represent as senile cells There are four groups- 1) Youth Group Cells within 33rd ceneration 2 represent as Youth Group. 2) Astragaloside Group Astragaloside dissolved in DMSO. and then treat HELF by DMSO  containing 0.1% Astragaloside. 3) Control Group: The same amount and concentration of DMSO was added into culture medium. 4) Senile Group The cells at the generation of 52 ~  2 represent as Senile Group 1 2 Drugs and Reagents
Carbapenem-resistant Acinetobacter baumannii (CRAb) is an important pathogen causing serious nosocomial infections. We describe an outbreak of CRAb in an intensive care unit in the Netherlands in 2021. During an outbreak of non-resistant A. baumannii, while infection control measures were in place, CRAb isolates carrying highly similar bla NDM-1 - and tet(x3)-encoding plasmids were isolated from three patients over a period of several months. The chromosomal and plasmid sequences of the CRAb and non-carbapenemase-carrying A. baumannii isolates cultured from patient materials were analysed using hybrid assemblies of short-read and long-read sequences. The CRAb isolates revealed that the CRAb outbreak consisted of two different strains, carrying similar plasmids. The plasmids contained multiple antibiotic resistance genes including the tetracycline resistance gene tet(x3), and the bla NDM-1 and bla OXA-97 carbapenemase genes. We determined minimal inhibitory concentrations (MICs) for 13 antibiotics, including the newly registered tetracycline antibiotics eravacycline and omadacycline. The CRAb isolates showed high MICs for tetracycline antibiotics including eravacycline and omadacycline, except for minocycline which had a low MIC. In this study we show the value of sequencing multidrug-resistant A. baumannii for outbreak tracking and guiding outbreak mitigation measures.
Long-course chemoradiation plus PD-1 inhibition (Tislelizumab 200mg, 3 times, 3-week interval) starting on Day 8 of radiation therapy. TME surgery is scheduled in 8\~12 weeks after completion of radiation.
This approach began with a self-examination in an extra-oral mirror by the participant to allow the professional to understand participant's perception of oral health, and the use of a plaque-disclosing solution to allow the participant to be more sensitive to the areas where brushing and flossing were not effective. Conditions such as caries lesions, major gingival recessions, areas of greater inflammation, areas where plaque accumulation or even tartar was more visible and further denture care were highlighted. The typodont (model) was then used to demonstrate the correct brushing and flossing technique. The session ended with the participant receiving an explanatory guide, a personalized plan, and more appropriate tools to promote the expected improvement in oral health. A question-and-answer session was used to clarify any doubts. This method took about approximately 20 minutes.
AIM: The Questionnaire for Medical Checkup of Old-Old (QMCOO) has been used nationwide in Japan as part of the health checkup for latter-stage older adults since the financial year 2020. Although the QMCOO is useful in screening for frailty, its cutoff values for predicting adverse health outcomes have rarely been assessed. Therefore, this study aimed to calculate the cutoff values for predicting all-cause mortality and disability incidence and to evaluate their predictive validity.
METHODS: This study included 3837 health checkup recipients aged ≥75 years residing in Higashiura Town, Aichi Prefecture, Japan. The health checkup was conducted from June 1, 2020, to January 31, 2021. Mortality and disability incidence were analyzed separately. For the latter, participants with a disability history were excluded, leaving 3040 available for analysis.
RESULTS: During the follow-up of 11 191 and 8550 person-years, 276 died and 438 developed a disability, respectively. The areas under the receiver operating characteristic curve (95% confidence intervals) for all-cause mortality and disability incidence were 0.68 (0.65-0.71) and 0.66 (0.63-0.68), respectively, with QMCOO cutoff values at 3/4 and 2/3 points. Cox proportional hazard models adjusted for age, sex, body mass index, self-reported diseases, and frequency of alcohol consumption demonstrated the predictive validity of those cutoff values.
CONCLUSIONS: The optimal cutoff value of the QMCOO for predicting all-cause mortality was 3/4, while the optimal cutoff value for predicting disability incidence was 2/3 among an older Japanese population. Geriatr Gerontol Int 2024; 24: 1203-1209.